In vitro interactions of LytA, the major pneumococcal autolysin, with two bacteriophage lytic enzymes (Cpl-1 and Pal), cefotaxime and moxifloxacin against antibiotic-susceptible and -resistant Streptococcus pneumoniae strains | Zendy

Violeta Rodríguez-Cerrato | Zendy; Pedro Garcı́a | Zendy; Gema del Prado | Zendy; Ernesto Garcı́a | Zendy; Matilde Gracia | Zendy; Lorena Huelves | Zendy; Carmen Ponte | Zendy; R. Castillo | Zendy; Francisco García Soriano | Zendy

Open Access

In vitro interactions of LytA, the major pneumococcal autolysin, with two bacteriophage lytic enzymes (Cpl-1 and Pal), cefotaxime and moxifloxacin against antibiotic-susceptible and -resistant Streptococcus pneumoniae strains

Author(s) -

Violeta Rodríguez-Cerrato,

Pedro Garcı́a,

Gema del Prado,

Ernesto Garcı́a,

Matilde Gracia,

Lorena Huelves,

Carmen Ponte,

R. Castillo,

Francisco García Soriano

Publication year - 2007

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkm342

Subject(s) - autolysin , cefotaxime , microbiology and biotechnology , streptococcus pneumoniae , lytic cycle , penicillin , antibiotics , biology , pneumococcal infections , moxifloxacin , virology , virus

In an innovative therapeutic exploitation against antibiotic-resistant Streptococcus pneumoniae, here we have evaluated the in vitro activity of a purified bacterially-encoded cell wall lytic enzyme, LytA (the major pneumococcal autolysin), and compared it with those of Cpl-1 and Pal (pneumococcal phage lytic enzymes) and two antibiotics versus four pneumococcal strains.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research